ARDELYX, INC. (ARDX)
ARDELYX, INC. (ARDX) from its SEC filings: 2025 revenue $407.3 million (+22% vs the year before), net margin -15%, free cash flow -$44.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $407.3 million |
| Revenue growth | +22% |
| Net income | -$62.0 million |
| Net margin | -15.2% |
| Free cash flow | -$44.0 million |
| Diluted EPS | $-0.26 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +24% |
| Cash | $97.2 million |
| Long-term debt | $0 |
| Share count, 1 year | +3% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.